Patients face uncertainty after discovering their source of affordable obesity drugs was unlicensed.

Patients who bought affordable obesity drugs from a website are now unsure of their options after discovering the compounding pharmacy lacked the necessary license. These patients stockpiled alternative GLP-1 drugs, raising concerns about the legality and safety of their purchases. The situation, reported by NPR's Sydney Lupkin, leaves both patients and medical facilities in uncertainty.

5 weeks ago
12 Articles